MedTrace Logo

The Role of GIP and GLP-2 in Postprandial Splanchnic Blood Flow Distribution and Metabolism

NCT05391581 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 10

Last updated 2023-12-26

No results posted yet for this study

Summary

This project will describe the mechanisms of action and the relative contributions of GIP and GLP-2 to changes in gastrointestinal blood flow induced by oral glucose, exogenous GIP and GLP-2 infusions, and endogenous GIP and GLP-2 with the use of two novel receptor antagonists GIP(3-30)NH2 and GLP-2(3-33) in healthy individuals.

Conditions

  • Blood Flow

Interventions

OTHER

GIPR antagonist / study tool

Selective antagonist of the GIPR, GIP(3-30)NH2

OTHER

GLP-2R antagonist / study tool

Selective antagonist of the GLP-2R, GLP-2(3-33)

OTHER

Placebo

Saline

Sponsors & Collaborators

  • Rigshospitalet, Denmark

    collaborator OTHER

  • University of Copenhagen

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
SINGLE
Model
CROSSOVER

Eligibility

Min Age
20 Years
Max Age
70 Years
Sex
MALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2022-01-13
Primary Completion
2023-02-07
Completion
2023-02-07

Countries

  • Denmark

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05391581 on ClinicalTrials.gov